IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: Implications in pathophysiology and translation to human disease

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  d'Hennezel, Eva ^a   Kornete, Mara ^a   Piccirillo, Ciriaco A ^b  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; JANUS KINASE 3; MICRORNA; MICRORNA 155; PROTEIN BCL 2; RAPAMYCIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL SURVIVAL; CELL THERAPY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE PREDISPOSITION; DNA METHYLATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION; GENETIC VARIABILITY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; INTRACELLULAR SIGNALING; KIDNEY CANCER; LOW DRUG DOSE; LYMPH NODE; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MELANOMA; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS; PANCREAS ISLET CELL; PANCREAS LYMPH NODE; PATHOPHYSIOLOGY; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; TEFF CELL; ANIMAL; IMMUNOLOGY; METABOLISM; MOUSE; PHYSIOLOGY; VALIDATION STUDY;

ANIMALS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2; MICE; MICE, INBRED NOD; T-LYMPHOCYTES, REGULATORY;

EID: 78049482203     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-113     Document Type: Article

References (101)

1. Piccirillo CA, d'Hennezel E, Sgouroudis E, Yurchenko E. CD4+Foxp3+ regulatory T cells in the control of autoimmunity: in vivo veritas. Curr Opin Immunol 2008, 20:655-662. 10.1016/j.coi.2008.09.006, 18926906.
2. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061. 10.1126/science.1079490, 12522256.
3. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6:1142-1151. 10.1038/ni1263, 16227984.
4. d'Hennezel E, Ben-Shoshan M, Ochs HD, Torgerson TR, Russell LJ, Lejtenyi C, Noya FJ, Jabado N, Mazer B, Piccirillo CA. FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome. N Engl J Med 2009, 361:1710-1713. 10.1056/NEJMc0907093, 19846862.
5. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:337-342. 10.1038/ni909, 12612581.
6. Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 2001, 19:131-161. 10.1146/annurev.immunol.19.1.131, 11244033.
7. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. AnnuRevImmunol 2005, 23:447-485.
8. Tritt M, Sgouroudis E, d'Hennezel E, Albanese A, Piccirillo CA. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 2008, 57:113-123. 10.2337/db06-1700, 17928397.
9. Sgouroudis E, Albanese A, Piccirillo CA. Impact of protective IL-2 allelic variants on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J Immunol 2008, 181:6283-6292.
10. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697. 10.1016/j.immuni.2008.03.016, 2394854, 18468463.
11. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12:431-440. 10.1016/S1074-7613(00)80195-8, 10795741.
12. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003, 171:3348-3352.
13. Kumanogoh A, Wang X, Lee I, Watanabe C, Kamanaka M, Shi W, Yoshida K, Sato T, Habu S, Itoh M, et al. Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. J Immunol 2001, 166:353-360.
14. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998, 70:1-81. full_text, 9755337.
15. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008, 26:453-479. 10.1146/annurev.immunol.26.021607.090357, 18062768.
16. Wolf M, Schimpl A, Hunig T. Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(-) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms. Eur J Immunol 2001, 31:1637-1645. 10.1002/1521-4141(200106)31:6<1637::AID-IMMU1637>3.0.CO;2-T, 11385607.
17. Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007, 119:482-487. 10.1016/j.jaci.2006.10.007, 17196245.
18. Roifman CM. Human IL-2 receptor alpha chain deficiency. Pediatr Res 2000, 48:6-11. 10.1203/00006450-200007000-00004, 10879793.
19. Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccio M, Oleastro M, Ornani A, Paz R, Rivarola MA, Zelazko M, Belgorosky A. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics 2006, 118:e1584-1592. 10.1542/peds.2005-2882, 17030597.
20. Lyons PA, Armitage N, Argentina F, Denny P, Hill NJ, Lord CJ, Wilusz MB, Peterson LB, Wicker LS, Todd JA. Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping. Genome Res 2000, 10:446-453. 10.1101/gr.10.4.446, 310860, 10779485.
21. Denny P, Lord CJ, Hill NJ, Goy JV, Levy ER, Podolin PL, Peterson LB, Wicker LS, Todd JA, Lyons PA. Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes 1997, 46:695-700. 10.2337/diabetes.46.4.695, 9075813.
22. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, Garner VE, Gonzalez-Munoz A, Clark J, Veijola R, Cubbon R, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 2007, 39:329-337. 10.1038/ng1958, 2886969, 17277778.
23. Encinas JA, Kuchroo VK. Genetics of experimental autoimmune encephalomyelitis. Curr Dir Autoimmun 1999, 1:247-272. full_text, 11791445.
24. Podolin PL, Wilusz MB, Cubbon RM, Pajvani U, Lord CJ, Todd JA, Peterson LB, Wicker LS, Lyons PA. Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene?. Cytokine 2000, 12:477-482. 10.1006/cyto.1999.0609, 10857762.
25. van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M, Wapenaar MC, Barnardo MC, Bethel G, Holmes GK, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007, 39:827-829. 10.1038/ng2058, 2274985, 17558408.
26. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, Bailey R, Nejentsev S, Field SF, Payne F, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007, 39:857-864. 10.1038/ng2068, 2492393, 17554260.
27. Zhernakova A, Alizadeh BZ, Bevova M, van Leeuwen MA, Coenen MJ, Franke B, Franke L, Posthumus MD, van Heel DA, van der Steege G, et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007, 81:1284-1288. 10.1086/522037, 2276343, 17999365.
28. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, Jones R, Ring SM, McArdle W, Pembrey ME, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 2005, 76:773-779. 10.1086/429843, 1199367, 15776395.
29. Qu HQ, Montpetit A, Ge B, Hudson TJ, Polychronakos C. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes 2007, 56:1174-1176. 10.2337/db06-1555, 17395754.
30. Qu HQ, Bradfield JP, Belisle A, Grant SF, Hakonarson H, Polychronakos C. The type I diabetes association of the IL2RA locus. Genes Immun 2009, 10(Suppl 1):S42-48. 10.1038/gene.2009.90, 2805446, 19956099.
31. Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, Bourget K, Plagnol V, Field S, Atkinson M, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007, 39:1074-1082. 10.1038/ng2102, 17676041.
32. Maier LM, Lowe CE, Cooper J, Downes K, Anderson DE, Severson C, Clark PM, Healy B, Walker N, Aubin C, et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 2009, 5:e1000322. 10.1371/journal.pgen.1000322, 2602853, 19119414.
33. Qu HQ, Verlaan DJ, Ge B, Lu Y, Lam KC, Grabs R, Harmsen E, Hudson TJ, Hakonarson H, Pastinen T, Polychronakos C. A cis-acting regulatory variant in the IL2RA locus. J Immunol 2009, 183:5158-5162. 10.4049/jimmunol.0901337, 19794070.
34. Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, Nutland S, Coleman G, Himsworth M, Hardy M, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009, 41:1011-1015. 10.1038/ng.434, 2749506, 19701192.
35. Klinker MW, Schiller JJ, Magnuson VL, Wang T, Basken J, Veth K, Pearce KI, Kinnunen L, Harjutsalo V, Wang X, et al. Single-nucleotide polymorphisms in the IL2RA gene are associated with age at diagnosis in late-onset Finnish type 1 diabetes subjects. Immunogenetics 2010, 62:101-107. 10.1007/s00251-009-0417-4, 20033399.
36. Kawasaki E, Awata T, Ikegami H, Kobayashi T, Maruyama T, Nakanishi K, Shimada A, Uga M, Kurihara S, Kawabata Y, et al. Genetic association between the interleukin-2 receptor-alpha gene and mode of onset of type 1 diabetes in the Japanese population. J Clin Endocrinol Metab 2009, 94:947-952. 10.1210/jc.2008-1596, 19106270.
37. Pop SM, Wong CP, Culton DA, Clarke SH, Tisch R. Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J Exp Med 2005, 201:1333-1346. 10.1084/jem.20042398, 2213147, 15837817.
38. Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005, 54:1407-1414. 10.2337/diabetes.54.5.1407, 15855327.
39. Chen Z, Herman AE, Matos M, Mathis D, Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 2005, 202:1387-1397. 10.1084/jem.20051409, 2212985, 16301745.
40. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009, 10:689-695. 10.1038/ni.1760, 19536194.
41. D'Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, Benoist C, Mathis D. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci USA 2008, 105:19857-19862. 10.1073/pnas.0810713105, 2604930, 19073938.
42. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, Barriot S, Garcia C, Waldmann H, Bach JF, Chatenoud L. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005, 54:1415-1422. 10.2337/diabetes.54.5.1415, 15855328.
43. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005, 6:1152-1159. 10.1038/ni1264, 16227983.
44. Malek TR, Porter BO, Codias EK, Scibelli P, Yu A. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J Immunol 2000, 164:2905-2914.
45. Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002, 17:167-178. 10.1016/S1074-7613(02)00367-9, 12196288.
46. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005, 201:723-735. 10.1084/jem.20041982, 15753206.
47. Burchill MA, Goetz CA, Prlic M, O'Neil JJ, Harmon IR, Bensinger SJ, Turka LA, Brennan P, Jameson SC, Farrar MA. Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol 2003, 171:5853-5864.
48. Antov A, Yang L, Vig M, Baltimore D, Van Parijs L. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 2003, 171:3435-3441.
49. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005, 201:723-735. 10.1084/jem.20041982, 2212841, 15753206.
50. Elliott EA, Flavell RA. Transgenic mice expressing constitutive levels of IL-2 in islet beta cells develop diabetes. Int Immunol 1994, 6:1629-1637. 10.1093/intimm/6.11.1629, 7865456.
51. Sgouroudis E, Piccirillo CA. Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease. Diabetes Metab Res Rev 2009, 25:208-218. 10.1002/dmrr.945, 19214972.
52. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 Is Essential for TGF-beta to Convert Naive CD4+CD25- Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells. J Immunol 2007, 178:2018-2027.
53. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009, 21:281-285. 10.1016/j.coi.2009.05.007, 2733784, 19500966.
54. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 2009, 106:1903-1908. 10.1073/pnas.0811556106, 2644136, 19174509.
55. Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, Rajewsky K, Rudensky AY. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009, 30:80-91. 10.1016/j.immuni.2008.11.010, 2654249, 19144316.
56. Jeker J, Bluestone JA. Small RNA regulators of T cell-mediated autoimmunity. J Clin Immunol 2010, 30:347-357. 10.1007/s10875-010-9392-7, 20393792.
57. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009, 32:189-194. 10.1016/j.jaut.2009.02.012, 2717629, 19303254.
58. Zhou X, Jeker LT, Fife BT, Zhu S, Anderson MS, McManus MT, Bluestone JA. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med 2008, 205:1983-1991. 10.1084/jem.20080707, 2526194, 18725525.
59. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002, 109:131-140. 150819, 11781358.
60. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99. 10.2337/diabetes.54.1.92, 15616015.
61. Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D, Haller M, Rockell J, Gottlieb P, Clare-Salzler M, Atkinson M. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 2007, 56:604-612. 10.2337/db06-1248, 17327427.
62. Putnam AL, Vendrame F, Dotta F, Gottlieb PA. CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 2005, 24:55-62. 10.1016/j.jaut.2004.11.004, 15725577.
63. Dendrou CA, Wicker LS. The IL-2/CD25 pathway determines susceptibility to T1 D in humans and NOD mice. J Clin Immunol 2008, 28:685-696. 10.1007/s10875-008-9237-9, 18780166.
64. Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, Ziegler SF, Roncarolo MG, Levings MK. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 2005, 115:3276-3284. 10.1172/JCI24685, 1242190, 16211090.
65. Passerini L, Allan SE, Battaglia M, Di Nunzio S, Alstad AN, Levings MK, Roncarolo MG, Bacchetta R. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. Int Immunol 2008, 20:421-431. 10.1093/intimm/dxn002, 18270368.
66. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108:1571-1579. 10.1182/blood-2006-02-004747, 1895505, 16645171.
67. Long SA, Cerosaletti K, Bollyky PL, Tatum M, Shilling H, Zhang S, Zhang ZY, Pihoker C, Sanda S, Greenbaum C, Buckner JH. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59:407-415. 10.2337/db09-0694, 19875613.
68. Jailwala P, Waukau J, Glisic S, Jana S, Ehlenbach S, Hessner M, Alemzadeh R, Matsuyama S, Laud P, Wang X, Ghosh S. Apoptosis of CD4+ CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS One 2009, 4:e6527. 10.1371/journal.pone.0006527, 2716541, 19654878.
69. Lennon GP, Bettini M, Burton AR, Vincent E, Arnold PY, Santamaria P, Vignali DA. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 2009, 31:643-653. 10.1016/j.immuni.2009.07.008, 2763021, 19818656.
70. Trudeau JD, Kelly-Smith C, Verchere CB, Elliott JF, Dutz JP, Finegood DT, Santamaria P, Tan R. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003, 111:217-223. 151866, 12531877.
71. Eisenbarth GS, Kotzin BL. Enumerating autoreactive T cells in peripheral blood: a big step in diabetes prediction. The Journal of Clinical Investigation 2003, 111:179-181. 151887, 12531872.
72. Wong CP, Stevens R, Long B, Li L, Wang Y, Wallet MA, Goudy KS, Frelinger JA, Tisch R. Identical beta cell-specific CD8(+) T cell clonotypes typically reside in both peripheral blood lymphocyte and pancreatic islets. J Immunol 2007, 178:1388-1395.
73. Pang S, Zhang L, Wang H, Yi Z, Li L, Gao L, Zhao J, Tisch R, Katz JD, Wang B. CD8(+) T cells specific for beta cells encounter their cognate antigens in the islets of NOD mice. Eur J Immunol 2009, 39:2716-2724. 10.1002/eji.200939408, 19658094.
74. Li L, He Q, Garland A, Yi Z, Aybar LT, Kepler TB, Frelinger JA, Wang B, Tisch R. beta cell-specific CD4+ T cell clonotypes in peripheral blood and the pancreatic islets are distinct. J Immunol 2009, 183:7585-7591. 10.4049/jimmunol.0901587, 19917704.
75. Oling V, Marttila J, Ilonen J, Kwok WW, Nepom G, Knip M, Simell O, Reijonen H. GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J Autoimmun 2005, 25:235-243. 10.1016/j.jaut.2005.09.018, 16263242.
76. Reijonen H, Novak EJ, Kochik S, Heninger A, Liu AW, Kwok WW, Nepom GT. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002, 51:1375-1382. 10.2337/diabetes.51.5.1375, 11978633.
77. Danke NA, Yang J, Greenbaum C, Kwok WW. Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. J Autoimmun 2005, 25:303-311. 10.1016/j.jaut.2005.08.007, 16249070.
78. Monti P, Scirpoli M, Rigamonti A, Mayr A, Jaeger A, Bonfanti R, Chiumello G, Ziegler AG, Bonifacio E. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes. J Immunol 2007, 179:5785-5792.
79. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006, 107:2409-2414. 10.1182/blood-2005-06-2399, 1473973, 16304057.
80. Yu A, Zhu L, Altman NH, Malek TR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 2009, 30:204-217. 10.1016/j.immuni.2008.11.014, 2962446, 19185518.
81. Slingluff CL, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004, 22:4474-4485. 10.1200/JCO.2004.10.212, 15542798.
82. Boyman O, Surh CD, Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 2006, 6:1323-1331. 10.1517/14712598.6.12.1323, 17223740.
83. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006, 311:1924-1927. 10.1126/science.1122927, 16484453.
84. Kamimura D, Bevan MJ. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med 2007, 204:1803-1812. 10.1084/jem.20070543, 2118678, 17664293.
85. Letourneau S, van Leeuwen EM, Krieg C, Martin C, Pantaleo G, Sprent J, Surh CD, Boyman O. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc Natl Acad Sci USA 2010, 107:2171-2176. 10.1073/pnas.0909384107, 2836659, 20133862.
86. Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol 2007, 19:162-172. 10.1016/j.smim.2007.02.008, 1995654, 17383196.
87. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009, 4:e5994. 10.1371/journal.pone.0005994, 2694984, 19543393.
88. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008, 7:458-462. 10.4161/cc.7.4.5454, 2886808, 18235249.
89. Monti P, Scirpoli M, Maffi P, Piemonti L, Secchi A, Bonifacio E, Roncarolo MG, Battaglia M. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 2008, 57:2341-2347. 10.2337/db08-0138, 2518485, 18559659.
90. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002, 51:638-645. 10.2337/diabetes.51.3.638, 11872661.
91. Long SA, Buckner JH. Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun 2008, 30:293-302. 10.1016/j.jaut.2007.12.012, 2431984, 18313267.
92. Zorn E, Mohseni M, Kim H, Porcheray F, Lynch A, Bellucci R, Canning C, Alyea EP, Soiffer RJ, Ritz J. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:382-388. 10.1016/j.bbmt.2008.12.494, 2678797, 19203731.
93. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007, 8:191-197. 10.1038/ni1428, 17136045.
94. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009, 30:656-665. 10.1016/j.immuni.2009.04.006, 2742482, 19464988.
95. Wang B, Tisch R. Parameters influencing antigen-specific immunotherapy for Type 1 diabetes. Immunologic Research 2008, 42:246-258. 10.1007/s12026-008-8090-5, 19052699.
96. Casares S, Hurtado A, McEvoy RC, Sarukhan A, von Boehmer H, Brumeanu TD. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 2002, 3:383-391. 10.1038/ni770, 11862219.
97. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998, 47:894-899. 10.2337/diabetes.47.6.894, 9604865.
98. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 2006, 203:2737-2747. 10.1084/jem.20061577, 2118162, 17116737.
99. Jain R, Tartar DM, Gregg RK, Divekar RD, Bell JJ, Lee HH, Yu P, Ellis JS, Hoeman CM, Franklin CL, Zaghouani H. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med 2008, 205:207-218. 10.1084/jem.20071878, 2234380, 18195074.
100. Homann D, Holz A, Bot A, Coon B, Wolfe T, Petersen J, Dyrberg TP, Grusby MJ, von Herrath MG. Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 1999, 11:463-472. 10.1016/S1074-7613(00)80121-1, 10549628.
101. Ziegler AG, Nepom GT. Prediction and pathogenesis in type 1 diabetes. Immunity 2010, 32:468-478. 10.1016/j.immuni.2010.03.018, 20412757.